Pierre Fabre Laboratories Wins Prestigious Galien International Prize for EBVALLO®
June 23, 2024, 3:35 pm
Location: United States, California, South San Francisco
Employees: 501-1000
Founded date: 2012
Total raised: $90.5M
Pierre Fabre Laboratories has been honored with the prestigious "Prix Galien International" Prize for their groundbreaking immunotherapy, EBVALLO®. This innovative treatment offers hope to patients with a rare cancer, post-transplant lymphoproliferative disorder positive for Epstein-Barr virus (EBV+ PTLD), who have exhausted other treatment options.
The Galien International Prize is a symbol of scientific excellence and innovation, recognizing recent health innovations that have a significant impact on patient care. EBVALLO® stood out for its unique manufacturing process and mechanism of action, delivering rapid and lasting clinical results in over 50% of cases. This is a game-changer for a disease with a grim prognosis, offering a ray of hope to those in need.
Pierre Fabre Laboratories' success in oncology, a key focus area for the company, is underscored by their collaboration with Atara Biotherapeutics. This partnership has enabled the global development, manufacturing, and commercialization of EBVALLO®, bringing this life-saving treatment to patients worldwide. With approvals from the European Medicines Agency and availability in select European countries, EBVALLO® is already making a difference in the lives of those battling this rare cancer.
"We are immensely proud to receive this prestigious award, which is a testament to our commitment to advancing patient care," said Éric Ducournau, CEO of Pierre Fabre Laboratories. "EBVALLO® represents a significant therapeutic advancement for patients facing a rare cancer with limited treatment options. Every individual we help brings us closer to our mission of making the world a better place."
This recognition from the Galien International Prize is a validation of Pierre Fabre Laboratories' dedication to innovation and patient-centric healthcare. As they continue to push the boundaries of oncology research, EBVALLO® stands as a beacon of hope for those in need of effective treatment options.
Contact: Laurence MARCHAL, laurence.marchal@pierre-fabre.com
For more information, visit: [link to original content]
Source: Pierre Fabre"
The Galien International Prize is a symbol of scientific excellence and innovation, recognizing recent health innovations that have a significant impact on patient care. EBVALLO® stood out for its unique manufacturing process and mechanism of action, delivering rapid and lasting clinical results in over 50% of cases. This is a game-changer for a disease with a grim prognosis, offering a ray of hope to those in need.
Pierre Fabre Laboratories' success in oncology, a key focus area for the company, is underscored by their collaboration with Atara Biotherapeutics. This partnership has enabled the global development, manufacturing, and commercialization of EBVALLO®, bringing this life-saving treatment to patients worldwide. With approvals from the European Medicines Agency and availability in select European countries, EBVALLO® is already making a difference in the lives of those battling this rare cancer.
"We are immensely proud to receive this prestigious award, which is a testament to our commitment to advancing patient care," said Éric Ducournau, CEO of Pierre Fabre Laboratories. "EBVALLO® represents a significant therapeutic advancement for patients facing a rare cancer with limited treatment options. Every individual we help brings us closer to our mission of making the world a better place."
This recognition from the Galien International Prize is a validation of Pierre Fabre Laboratories' dedication to innovation and patient-centric healthcare. As they continue to push the boundaries of oncology research, EBVALLO® stands as a beacon of hope for those in need of effective treatment options.
Contact: Laurence MARCHAL, laurence.marchal@pierre-fabre.com
For more information, visit: [link to original content]
Source: Pierre Fabre"